With the objectives of improving response rate, duration of response, and survival in small-
cell carcinoma of the lung, 39 patients were randomized to remission-induction with either …

Abstract From September 1986 until December 1991, 139 patients with histologically-proven
small cell lung cancer, age< 75 years, performance status> 40, absence of brain metastases …

Small cell lung cancer (SCLC) was initially recognized as an entity distinct from other types
of lung cancer by pathologic examination in 1926 by Dr. Barnard [1]. It has been commonly …

PURPOSE To evaluate the activity and toxicity of the combination carboplatin plus
vinorelbine in extensive small-cell lung cancer (SCLC). PATIENTS AND METHODS A two …

Abstract SIXTY-TWO PATIENTS with previously untreated limited stage small cell lung
cancer were treated in a prospectively randomized trial comparing thoracic irradiation plus …

Abstract From December 1987 through April 1989, 40 patients with extensive‐stage small
cell carcinoma of the lung were enrolled in a Hoosier Oncology Group (HOG) trial using …

In an attempt to circumvent innate or acquired tumor-cell resistance to chemotherapy,
patients with small-cell lung cancer (SCLC) were treated with induction therapy that …

The National Cancer Institute of Canada Clinical Trials Group conducted a prospective
randomized study comparing standard chemotherapy with alternating chemotherapy in …

Eighty-three patients with histologically proven small cell carcinoma of the lung were
entered into a prospective randomised clinical trial to evaluate two induction regimes. A …

Small cell lung cancer requires aggressive combination chemotherapy. The three active
agents, doxorubicin (A) 45 mg/m 2 iv day 1, cyclophosphamide (C) 1.0 mg/m 2 iv day 1 and …